Fischer Medical (FISCHER)

FairStock Score: 27/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter shows ₹101 Cr sales and ₹19 Cr net profit, demonstrating recent operational turnaround momentum.
• Sales growth of 760.43% and profit growth of 1000.00% indicate a rapidly expanding business, at least in the short term.
• Low debt/equity of 0.10 provides financial cushion and limits balance-sheet risk.
• Promoter holding of 61.80% aligns management's interests with public shareholders.
• Piotroski F-Score of 7/9 suggests recent improvements in financial fundamentals.

Concerns

• ROE of -2.88% and ROCE of 1.08% mean the business is not currently earning an acceptable return on capital.
• P/E of 62.70 and P/B of 29.86 leave a very thin margin of safety relative to book value of ₹1.25.
• Stock has fallen from 52-week high of ₹124.70 to ₹37.33, showing extreme volatility and market skepticism.
• Dividend yield of 0.01% gives no income support while waiting for growth to materialize.

AI Analysis

At ₹37.33, Fischer Medical reminds me of a stock that has been through the boom-and-bust wringer: it fell from ₹124.70 to near its 52-week low. Value investing is about buying durable earning power at a discount, and I do not see that here. Sales grew 760.43% and profit grew 1000%, and the latest quarter delivered ₹101 Cr of sales and ₹19 Cr of net profit. That sounds promising. But look at the quality: return on equity is minus 2.88%, and return on capital employed is only 1.08%. A business that cannot generate a return on its shareholders' money is not a wonderful business, no matter how fast sales are growing. The 62.70 P/E and 29.86 P/B are betting on perfection. With book value of only ₹1.25 per share, the market is paying 30 times book for a company with a 0.01% dividend yield and a FairStock Score of 24/100. There is some comfort: debt/equity is just 0.10, promoter holding is high at 61.80%, and the Piotroski score of 7/9 suggests recent improvements. But 1,000% profit growth from a small base is not a durable moat. This looks more like a potential turnaround than a proven compounder. I would need strong proof that the ₹19 Cr quarterly profit can repeat, that ROE turns and stays positive, and that cash follows earnings. Until then, the price says risk is high and margin of safety is absent.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer